ALX2004 — Interim data
2H 2026
ALX Oncology plans to share safety data from the dose-escalation phase of this trial in 2H 2026.Source filing
ALXO biotech catalysts & pipeline
ALX ONCOLOGY HOLDINGS INC · Data as of 2026-09-08
Upcoming catalysts
evorpacept — Interim data
Q3 2026
The Phase 2 ASPEN-09-Breast Cancer clinical trial of evorpacept plus trastuzumab and physician's choice chemotherapy in patients with HER2+ breast cancer previously treated with ENHERTU® (fam-trastuzumab deruxtecan-nxki) is on track to begin enrollment in Q4 2025, with interim data expected in Q3 2026.Source filing
evorpacept — Topline data
mid-2027
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer –Source filing